We're Here for You!
The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.
I am a...
In this week’s blog, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie thoroughly discusses details on Tecvayli (teclistamab-cqyv)— a new bispecific antibody that was recently approved by the FDA for the treatment of relapsed or refractory multiple myeloma (RRMM). He delves into overall findings from the MajesTEC-1 Trial; in-hospital step-up dose schedule for teclistamab treatments; as well as follow-up treatment and supportive care. READ THE BLOG.
The IMF is grateful for you for helping us to reach our GivingTuesday goal. Because of you, the IMF can continue our research toward a cure, grow our support programs, develop our educational materials, and advocate for myeloma patients everywhere. Thank you for making good happen! We are still $8,000 shy of our goal. Will you help us surpass our goal of $75,000? DONATE NOW.
On November 22, 2022, GSK announced it has initiated the process for withdrawal of the U.S. marketing authorization for Blenrep (belantamab mafadotin-blmf) following the request of the U.S Food and Drug administration (FDA). This request was based upon the previously announced outcome of the DREAMM-3 phase III confirmatory trial which did not meet the requirements of the FDA Accelerated Approval regulations. Read the full update here.
The “Best of ASH 2022: What Patients and Care Partners Need to Know” will take place on Tuesday, December 20, 2022, at 4:00 p.m. PST | 6:00 p.m. CST | 7:00 p.m. EST. In this webinar, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G. M. Durie will summarize key takeaways from the 2022 American Society of Hematology (ASH) Annual Meeting that impact the myeloma community. Dr. Durie will also host a panel discussion highlighting the patient perspective with Linda Huguelet, IMF Support Group Leader of Chatanooga, TN; and Nick Lenoir, IMF Support Group Co-leader of Brooksville, FL. REGISTER NOW.
The speakers for this webinar were Jens Hillengass, MD, PhD (Roswell Park Comprehensive Cancer Center, Buffalo, NY) and IMF Nurse Leadership Board member Beth Faiman, PhD, MSN, APRN-BC, AOCN®, FAAN (Cleveland Clinic – Taussig Cancer Institute). They review why bone health is so important in myeloma, provide tips on living well with myeloma bone disease, give guidelines for physical activity, and more. WATCH THE REPLAY.
This IMF Patient and Family Webinar focuses on “Understanding the New Myeloma Landscape.” The speakers for this event include IMF Chairman of the Board and Chief Scientific Officer Brian G.M. Durie; S. Vincent Rajkumar, MD (Mayo Clinic – Rochester, MN); Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN (Cleveland Clinic – Taussig Cancer Institute); and Alfred L. Garfall, MD, MS (University of Pennsylvania – Philadelphia). There is a special focus on new immune therapies, including Tecvayli™ (teclistamab-cqyv), as well as available clinical trials. WATCH THE REPLAY.
Our hearts go to all innocent victims of the ongoing conflict in Ukraine.
As a global organization, the International Myeloma Foundation supports — and will continue to support — every myeloma patient, caregiver, doctor, researcher, and advocate going through struggles and difficulties brought about by the war in Ukraine.
As an advocate for hope and resilience among the members of the myeloma community, the IMF is here for you — and even to a greater degree, during this most difficult time.
Our mission is clear, and our steadfast commitment continues — to improve the quality of life of myeloma patients across the globe, while working toward prevention and a cure.
Need assistance in creating a fundraiser? The IMF team is here for you. Find out how you can help in the fight against myeloma today!
